News in the treatment of metastatic HER2 positive breast cancer

01/2021

MUDr. Lucie Reifová

Ústav radiační onkologie, Nemocnice Na Bulovce, Praha

SUMMARY

Metastatic breast cancer is still an uncurable disease. The prognosis of patients with HER2-positive metastatic breast cancer before the implementation of trastuzumab was poor. This targeted treatment to receptors dramatically improved the fate of patients regarding overall survival and a decrease in difficulties. A number of effective drugs has been invented since trastuzumab was implemented as the standard treatment in the last century - pertuzumab, trastuzumab emtansin (T-DM1) and lapatinib. Despite this almost all patients will suffer progression of disease and it is necessary to develop new drugs and methods. This type of cancer metastasizes to the brain very often and new drugs seem to be effective in that situation.

Key words

HER2-positive breast cancer, triple positive breast cancer, trastuzumab deruxtecan, tucatinib